Myriad Genetics rallies as surprise profit and oncology demand signal turnaround
Myriad Genetics (NASDAQ:MYGN) shares rose as much as 4.9% Tuesday morning after the company reported fourth-quarter results that significantly outpaced Wall Street expectations for both the top and bottom lines.





-640x360.jpg&w=1200&q=75)
-640x360.jpg&w=1200&q=75)













